Intranasal and oral vaccination with protein-based antigens: Advantages, challenges and formulation strategies

Protein and Cell

Volumn 6, Issue 7, 2015, Pages 480-503

  Wang, Shujing ^a   Liu, Huiqin ^a   Zhang, Xinyi ^a   Qian, Feng ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Adjuvant; Immunostimulant; Mucosal vaccine; Protein antigen; Vaccine delivery system

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA TOCOPHEROL; ALUMINUM POTASSIUM SULFATE; ANTIGEN; BACTERIAL DNA; BACTERIAL TOXIN; CHITOSAN; COMPOUND 48-80; CYTOKINE; DEXTRAN; DOUBLE STRANDED RNA; EUDRAGIT; GLYCOLIPID; GOLD NANOPARTICLE; HYALURONIC ACID; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOSTIMULATING AGENT; LIPID; LIPOSOME; NIOSOME; PEPTIDOGLYCAN; POLYGLUTAMIC ACID; SAPONIN; STARCH; VIROSOME; VIRUS LIKE PARTICLE VACCINE; IMMUNOLOGICAL ADJUVANT; PROTEIN;

ANTIGEN PRESENTATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; VACCINATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; PROTEINS; VACCINATION;

EID: 84943359553     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-015-0164-2     Document Type: Review

References (247)

1. Abusugra I, Morein B (1999) Iscom is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses. FEMS Immunol Med Microbiol 23:5–12
2. Ali R, Kumar S, Naqvi RA, Sheikh IA, Rao DN (2013) Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice. Int Immunopharmacol 15:97–105
3. Almeida AJ, Alpar HO (1996) Nasal delivery of vaccines. J Drug Target 3:455–467
4. Alpar HO, Eyles JE, Williamson ED, Somavarapu S (2001) Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 51:173–201
5. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787–796
6. Bal SM, Slutter B, Verheul R, Bouwstra JA, Jiskoot W (2012) Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 45:475–481
7. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK (1998) Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 72:1345–1353
8. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
9. Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V (2013) Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Int J Pharm 441:636–642
10. Baudner BC, O’Hagan DT (2010) Bioadhesive delivery systems for mucosal vaccine delivery. J Drug Target 18:752–770
11. Belyakov IM, Moss B, Strober W, Berzofsky JA (1999) Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 96:4512–4517
12. Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A (2007) Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 32:278–290
13. Borges O, Cordeiro-da-Silva A, Tavares J, Santarem N, de Sousa A, Borchard G, Junginger HE (2008) Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 69:405–416
14. Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR (1999) IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 162:122–128
15. Brandhonneur N, Loizel C, Chevanne F, Wakeley P, Jestin A, Le Potier MF, Le Corre P (2009) Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Int J Pharm 373:16–23
16. Brunner R, Jensen-Jarolim E, Pali-Scholl I (2010) The ABC of clinical and experimental adjuvants–a brief overview. Immunol Lett 128:29–35
17. Buffa V, Klein K, Fischetti L, Shattock RJ (2012) Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. Plos One 7:e50529
18. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515–518
19. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, Johnston RE (1997) Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71:3031–3038
20. Carcaboso AM, Hernandez RM, Igartua M, Gascon AR, Rosas JE, Patarroyo ME, Pedraz JL (2003) Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 260:273–282
21. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O’Hagan DT (1992) Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76:164–168
22. Chen YS, Hung YC, Lin WH, Huang GS (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21:195101
23. Chen J, Li Z, Huang H, Yang Y, Ding Q, Mai J, Guo W, Xu Y (2011) Improved antigen cross-presentation by polyethyleneiminebased nanoparticles. Int J Nanomed 6:77–84
24. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH (2001) Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20:208–217
25. Cortesi R, Ravani L, Rinaldi F, Marconi P, Drechsler M, Manservigi M, Argnani R, Menegatti E, Esposito E, Manservigi R (2013) Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 440:229–237
26. Courtney AN, Nehete PN, Nehete BR, Thapa P, Zhou DP, Sastry KJ (2009) Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 27:3335–3341
27. Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37:511–539
28. Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG (2012) Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 509:143–163
29. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC (2014) State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 187:133–144
30. De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597–6601
31. De Gregorio E, Rappuoli R (2014) From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 14:505–514
32. Degim IT, Celebi N (2007) Controlled delivery of peptides and proteins. Curr Pharm Des 13:99–117
33. Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM (2011) Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 29:294–306
34. Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M (2010) Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix (TM), the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine. Hum Vaccines 6:407–419
35. Devriendt B, De Geest BG, Goddeeris BM, Cox E (2012) Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. J Control Release 160:431–439
36. Dormitzer PR, Grandi G, Rappuoli R (2012) Structural vaccinology starts to deliver. Nat Rev Microbiol 10:807–813
37. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y (2007) Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25:2832–2838
38. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y et al (2013a) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587
39. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ et al (2013b) Identification of a receptorbinding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87:9939–9942
40. Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA (2001) Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19:1636–1642
41. Ebensen T, Schulze K, Riese P, Morr M, Guzman CA (2007) The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol 14:952–958
42. Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzman CA (2011) Bis-(3’,5’)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29:5210–5220
43. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J (2007) “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother 30:378–395
44. Ellis JA, West KH, Waldner C, Rhodes C (2005) Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J 46:155–162
45. Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO (1998) Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16:698–707
46. Eyles JE, Williamson ED, Spiers ID, Stagg AJ, Jones SM, Alpar HO (2000) Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J Control Release 63:191–200
47. Florindo HF, Pandit S, Lacerda L, Goncalves LMD, Alpar HO, Almeida AJ (2009) The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsiloncaprolactone- based nanoparticles. Biomaterials 30:879–891
48. Fujita Y, Taguchi H (2011) Current status of multiple antigenpresenting peptide vaccine systems: application of organic and inorganic nanoparticles. Chem Cent J 5:48
49. Garcia A, De Sanctis JB (2014) An overview of adjuvant formulations and delivery systems. APMIS 122:257–267
50. Garcia-Fuentes M, Alonso MJ (2012) Chitosan-based drug nanocarriers: where do we stand? J Control Release 161:496–504
51. Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jerome C, Marchand-Brynaert J et al (2007) PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120:195–204
52. Gherardi MM, Esteban M (2005) Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86:2925–2936
53. Gosselin EJ, Bitsaktsis C, Li Y, Iglesias BV (2009) Fc receptortargeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and nonmucosal pathogens. Arch Immunol Ther Exp (Warsz) 57:311–323
54. Graham RL, Donaldson EF, Baric RS (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836–848
55. Grgacic EV, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60–65
56. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK (2001) Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75:9713–9722
57. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP (2007) M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 15:701–713
58. Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63:943–955
59. Hiroi T, Goto H, Someya K, Yanagita M, Honda M, Yamanaka N, Kiyono H (2001) HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167:5862–5867
60. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45–53
61. Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A, Morein B (1998) The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 113:235–243
62. Hu KF, Lovgren-Bengtsson K, Morein B (2001) Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 51:149–159
63. Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang K, Shen T, Wang H, Tian P, Zhang L et al (2009) A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 4: e4180
64. Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W et al (2013) M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One 8:e59081
65. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T et al (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910–2919
66. Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J et al (2006) Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J Med Virol 78:954–963
67. Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL (1998) Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 56:63–73
68. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliver Rev 51:81–96
69. Ishii M, Kojima N (2010) Mucosal adjuvant activity of oligomannosecoated liposomes for nasal immunization. Glycoconj J 27:115–123
70. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788–792
71. Jaganathan KS, Vyas SP (2006) Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24:4201–4211
72. Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A, Vyas SP (2005) Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D, L-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 294:23–32
73. Jain AK, Goyal AK, Mishra N, Vaidya B, Mangal S, Vyas SP (2010) PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm 387:253–262
74. Jain S, Harde H, Indulkar A, Agrawal AK (2014) Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine 10:431–440
75. Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B, Moscoso CG, Chen CC, Niikura M, Cheng RH (2013) Chimeric hepatitis E virus-like particle as a carrier for oraldelivery. Vaccine 31:417–424
76. Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, Choi YJ, Cho CS (2014) Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 35:2365–2373
77. Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong WP, Wang LS, Nabel GJ (2013) Selfassembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102–106
78. Kang SM, Guo L, Yao Q, Skountzou I, Compans RW (2004) Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 78:9624–9632
79. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552–559
80. Kavanagh OV, Earley B, Murray M, Foster CJ, Adair BM (2003) Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-coglycolide) microspheres. Vaccine 21:4472–4480
81. Kavanagh OV, Adair BM, Welsh MD, Earley B (2013) Local and systemic immune responses in mice to intranasal delivery of peptides representing bovine respiratory syncytial virus epitopes encapsulated in poly (DL-lactide-co-glycolide) microparticles. Res Vet Sci 94:809–812
82. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E et al (1997) CD1d-restricted and TCR-mediated activation of valpha14, NKT cells by glycosylceramides. Science 278:1626–1629
83. Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y et al (2009) TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem Biophys Res Commun 384:296–300
84. Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S et al (2010) Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol 84:12703–12712
85. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL et al (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369–377
86. Khader SA, Gaffen SL, Kolls JK (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2:403–411
87. Kim SH, Lee KY, Kim J, Park SM, Park BK, Jang YS (2006) Identification of a peptide enhancing mucosal and systemic immune responses against EGFP after oral administration in mice. Mol Cells 21:244–250
88. Kim SH, Seo KW, Kim J, Lee KY, Jang YS (2010) The M celltargeting ligand promotes antigen delivery and induces antigenspecific immune responses in mucosal vaccination. J Immunol 185:5787–5795
89. Klinman DM, Currie D, Gursel I, Verthelyi D (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199:201–216
90. Klippstein R, Pozo D (2010) Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 6:523–529
91. Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K (2013) Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol 26:133–142
92. Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S et al (2013) Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 81:1625–1634
93. Koping-Hoggard M, Sanchez A, Alonso MJ (2005) Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 4:185–196
94. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549
95. Krugman S (1982) The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA 247:2012–2015
96. Lamphear BJ, Jilka JM, Kesl L, Welter M, Howard JA, Streatfield SJ (2004) A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine 22:2420–2424
97. Lawson LB, Norton EB, Clements JD (2011) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 23:414–420
98. Lema D, Garcia A, De Sanctis JB (2014) HIV vaccines: a brief overview. Scand J Immunol 80:1–11
99. Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G (2007) Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25:4223–4234
100. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D et al (2009) Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999
101. Lewis JS, Zaveri TD, Crooks CP 2nd, Keselowsky BG (2012) Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials 33:7221–7232
102. Li T, Takeda N, Miyamura T (2001) Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 19:3476–3484
103. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454
104. Li K, Chen D, Zhao X, Hu H, Yang C, Pang D (2011a) Preparation and investigation of Ulex europaeus agglutinin I-conjugated liposomes as potential oral vaccine carriers. Arch Pharm Res 34:1899–1907
105. Li K, Zhao X, Xu S, Pang D, Yang C, Chen D (2011b) Application of Ulex europaeus agglutinin I-modified liposomes for oral vaccine: Ex Vivo bioadhesion and in Vivo immunity. Chem Pharm Bull (Tokyo) 59:618–623
106. Libanova R, Ebensen T, Schulze K, Bruhn D, Norder M, Yevsa T, Morr M, Guzman CA (2010) The member of the cyclic dinucleotide family bis-(3′,5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant (vol 28, pg 2249, 2010). Vaccine 28:3625–3625
107. Liu X, Chen DW, Xie LP, Zhang RQ (2003) Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Control Release 93:293–300
108. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L et al (2011) Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol 85:4025–4030
109. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227–231
110. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12:592–605
111. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S (2014a) Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 32:2100–2108
112. Ma T, Wang L, Yang T, Ma G, Wang S (2014b) M-cell targeted polymeric lipid nanoparticles containing a toll-like receptor agonist to boost oral immunity. Int J Pharm 473:296–303
113. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E (2014) Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 111:12294–12299
114. Malik B, Goyal AK, Markandeywar TS, Rath G, Zakir F, Vyas SP (2012) Microfold-cell targeted surface engineered polymeric nanoparticles for oral immunization. J Drug Target 20:76–84
115. Maloy KJ, Donachie AM, O’Hagan DT, Mowat AM (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81:661–667
116. Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA (2006) Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38:90–95
117. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA (2009) Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27:3643–3649
118. Mann JF, Stieh D, Klein K, de Stegmann DS, Cranage MP, Shattock RJ, McKay PF (2012) Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. J Control Release 158:240–249
119. Mansoor F, Earley B, Cassidy JP, Markey B, Foster C, Doherty S, Welsh MD (2014) Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci 96:551–557
120. Marasini N, Skwarczynski M, Toth I (2014) Oral delivery of nanoparticle- based vaccines. Expert Rev Vaccines 13:1361–1376
121. Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8:934–943
122. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287–293
123. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ (1996) Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 93:5335–5340
124. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628–1632
125. Mathew S, Lendlein A, Wischke C (2014) Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery. Eur J Pharm Biopharm 87:403–407
126. Matsuo K, Koizumi H, Akashi M, Nakagawa S, Fujita T, Yamamoto A, Okada N (2011) Intranasal immunization with poly(gammaglutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 152:310–316
127. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180
128. McCluskie MJ, Davis HL (1998) Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161:4463–4466
129. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950–957
130. McDermott MR, Heritage PL, Bartzoka V, Brook MA (1998) Polymergrafted starch microparticles for oral and nasal immunization. Immunol Cell Biol 76:256–262
131. Meng S, Liu Z, Xu L, Li L, Mei S, Bao L, Deng W, Li L, Lei R, Xie L et al (2011) Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS One 6:e19863
132. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N (2003) Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 89:189–197
133. Mirchamsy H, Manhouri H, Hamedi M, Ahourai P, Fateh G, Hamzeloo Z (1996) Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Biologicals 24:343–350
134. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457–460
135. Morris CB, Cheng E, Thanawastien A, Cardenas-Freytag L, Clements JD (2000) Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine 18:1944–1951
136. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO (2004) Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 82:628–637
137. Mould JA, Drury JE, Frings SM, Kaupp UB, Pekosz A, Lamb RA, Pinto LH (2000) Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 275:31038–31050
138. Mowat AM, Smith RE, Donachie AM, Furrie E, Grdic D, Lycke N (1999) Oral vaccination with immune stimulating complexes. Immunol Lett 65:133–140
139. Mummert ME (2005) Immunologic roles of hyaluronan. Immunol Res 31:189–206
140. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350:896–903
141. Muzzarelli RA (2010) Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 8:292–312
142. Nagase S, Doyama R, Yagi K, Kondoh M (2013) Recent advances in claudin-targeting technology. Biol Pharm Bull 36:708–714
143. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157–1163
144. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–158
145. Neutra MR, Frey A, Kraehenbuhl JP (1996) Epithelial M cells: gateways for mucosal infection and immunization. Cell 86:345–348
146. Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Kawaguchi A, Hasegawa H, Kajino K, Ninomiya T et al (2013) Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano 7:3926–3938
147. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47
148. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N et al (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9:572–578
149. Noh YW, Hong JH, Shim SM, Park HS, Bae HH, Ryu EK, Hwang JH, Lee CH, Cho SH, Sung MH et al (2013) Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew Chem Int Ed Engl 52:7684–7689
150. Oliveira CR, Rezende CM, Silva MR, Pego AP, Borges O, Goes AM (2012) A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 6:e1894
151. Olszewska W, Steward MW (2001) Nasal delivery of epitope based vaccines. Adv Drug Deliv Rev 51:161–171
152. Pandey RS, Dixit VK (2010) Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target 18:282–291
153. Park CG (2014) Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo. Clin Exp Vaccine Res 3:149–154
154. Park YM, Lee SJ, Kim YS, Lee MH, Cha GS, Jung ID, Kang TH, Han HD (2013) Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw 13:177–183
155. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11: S63–68
156. Patel GB, Chen W (2010) Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines 9:431–440
157. Patel GB, Zhou HY, Ponce A, Chen WX (2007) Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 25:8622–8636
158. Patel GB, Ponce A, Zhou H, Chen W (2008) Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int J Toxicol 27:329–339
159. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA, Cox RJ (2011) Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 6:e26973
160. Petersson P, Hedenskog M, Alves D, Brytting M, Schroder U, Linde A, Lundkvist A (2010) The Eurocine (R) L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 28:6491–6497
161. Pogrebnyak N, Golovkin M, Andrianov V, Spitsin S, Smirnov Y, Egolf R, Koprowski H (2005) Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci USA 102:9062–9067
162. Porporatto C, Bianco ID, Correa SG (2005) Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol 78:62–69
163. Prevec L, Schneider M, Rosenthal KL, Belbeck LW, Derbyshire JB, Graham FL (1989) Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol 70:429–434
164. Pun PB, Bhat AA, Mohan T, Kulkarni S, Paranjape R, Rao DN (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9:468–477
165. Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–587
166. Rappuoli R, Aderem A (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:463–469
167. Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H (2001) Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 83:93–105
168. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23–32
169. Reineke JJ, Cho DY, Dingle YT, Morello AP 3rd, Jacob J, Thanos CG, Mathiowitz E (2013) Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc Natl Acad Sci USA 110:13803–13808
170. Renegar KB, Small PA Jr, Boykins LG, Wright PF (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978–1986
171. Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LH, Good M, Batzloff MR, Middelberg AP (2013) Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31:1950–1955
172. Rose MA, Zielen S, Baumann U (2012) Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 11:595–607
173. Rydell N, Sjoholm I (2004) Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22:1265–1274
174. Rydell N, Sjoholm I (2005) Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine 23:2775–2783
175. Rydell N, Stertman L, Sjoholm I (2005) Starch microparticles as vaccine adjuvant. Expert Opin Drug Deliv 2:807–828
176. Sahdev P, Ochyl LJ, Moon JJ (2014) Biomaterials for nanoparticle vaccine delivery systems. Pharm Res 31:2563–2582
177. Sajadi Tabassi SA, Tafaghodi M, Jaafari MR (2008) Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 360:12–17
178. Sanchez MV, Ebensen T, Schulze K, Cargnelutti D, Blazejewska P, Scodeller EA, Guzman CA (2014) Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One 9:e104824
179. Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOMbased vaccines: the second decade. Immunol Cell Biol 83:119–128
180. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS (2008) An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26:1846–1854
181. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK (2006) Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 24:45–56
182. Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, Kammona O, Kiparissides C, Bernkop-Schnurch A (2011) In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 32:4052–4057
183. Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH (2009) TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 38:362–369
184. Scheerlinck JP, Greenwood DL (2008) Virus-sized vaccine delivery systems. Drug Discov Today 13:882–887
185. Scolnick EM, McLean AA, West DJ, McAleer WJ, Miller WJ, Buynak EB (1984) Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 251:2812–2815
186. Seder RA, Hill AV (2000) Vaccines against intracellular infections requiring cellular immunity. Nature 406:793–798
187. Senchi K, Matsunaga S, Hasegawa H, Kimura H, Ryo A (2013) Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol 4:346
188. Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R et al (2005) Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and gardasil (R) vaccine samples. Hum Vaccines 1:191–197
189. Sharma S, Mukkur TK, Benson HA, Chen Y (2009) Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98:812–843
190. Shaw N, Ouyang SY, Liu ZJ (2013) Binding of bacterial secondary messenger molecule c di-GMP is a STING operation. Protein Cell 4:117–129
191. Sheppard NC, Brinckmann SA, Gartlan KH, Puthia M, Svanborg C, Krashias G, Eisenbarth SC, Flavell RA, Sattentau QJ, Wegmann F (2014) Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. Int Immunol 26:531–538
192. Shibata Y, Honda I, Justice JP, Van Scott MR, Nakamura RM, Myrvik QN (2001) Th1 adjuvant N-acetyl-D-glucosamine polymer upregulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect Immun 69:6123–6130
193. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP (2008) Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 11:58–66
194. Shukla A, Katare OP, Singh B, Vyas SP (2010) M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 385:47–52
195. Shukla A, Singh B, Katare OP (2011) Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol 164:820–827
196. Singh M, O’Hagan D (1998) The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv Drug Deliv Rev 34:285–304
197. Singh M, Briones M, O’Hagan DT (2001) A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70:267–276
198. Singh J, Pandit S, Bramwell VW, Alpar HO (2006) Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38:96–105
199. Skene CD, Sutton P (2006) Saponin-adjuvanted particulate vaccines for clinical use. Methods 40:53–59
200. Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM (2007) Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 81:1083–1094
201. Smith DM, Simon JK, Baker JR Jr (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13:592–605
202. Sneh-Edri H, Likhtenshtein D, Stepensky D (2011) Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol Pharm 8:1266–1275
203. Somavarapu S, Pandit S, Gradassi G, Bandera M, Ravichandran E, Alpar OH (2005) Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles. Int J Pharm 298:344–347
204. Specht EA, Mayfield SP (2014) Algae-based oral recombinant vaccines. Front Microbiol 5:60
205. Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW (2011) Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 6:e16532
206. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J et al (2006) Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80:4962–4970
207. Sui ZW, Chen QJ, Fang F, Zheng M, Chen Z (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690–7698
208. Sun HX, Xie Y, Ye YP (2009a) Advances in saponin-based adjuvants. Vaccine 27:1787–1796
209. Sun HX, Xie Y, Ye YP (2009b) ISCOMs and ISCOMATRIX. Vaccine 27:4388–4401
210. Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nostbakken JK, Jul-Larsen A, Guzman CA, Montomoli E, Lapini G, Piccirella S et al (2013) A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses 7:1181–1193
211. Tafaghodi M, Rastegar S (2010) Preparation and in vivo study of dry powder microspheres for nasal immunization. J Drug Target 18:235–242
212. Takahashi H (2003) Antigen presentation in vaccine development. Comp Immunol Microbiol Infect Dis 26:309–328
213. Tam JP (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85:5409–5413
214. Tamura S, Kurata T (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57:236–247
215. Tao W, Ziemer KS, Gill HS (2014) Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (Lond) 9:237–251
216. Thomas C, Gupta V, Ahsan F (2009) Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 379:41–50
217. Tiwari S, Agrawal GP, Vyas SP (2010) Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine (Lond) 5:1617–1640
218. Tiwari B, Agarwal A, Kharya AK, Lariya N, Saraogi G, Agrawal H, Agrawal GP (2011a) Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route. J Liposome Res 21:181–193
219. Tiwari S, Verma SK, Agrawal GP, Vyas SP (2011b) Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. Int J Pharm 413:211–219
220. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270–275
221. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160
222. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251–276
223. Tripathi V, Chitralekha KT, Bakshi AR, Tomar D, Deshmukh RA, Baig MA, Rao DN (2006) Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine 24:3279–3289
224. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, Colonna M, Steinman RM (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105:2574–2579
225. Turner TM, Jones LP, Tompkins SM, Tripp RA (2013) A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol 87:10792–10804
226. Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B (2011) Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 6:e17642
227. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan for mucosal vaccination. Adv Drug Deliv Rev 52:139–144
228. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778–4782
229. van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H (2014) Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev 74:28–34
230. Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM (2011) Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29:5221–5231
231. Vicente S, Peleteiro M, Diaz-Freitas B, Sanchez A, Gonzalez- Fernandez A, Alonso MJ (2013) Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release 172:773–781
232. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL, Alonso MJ (2004) PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17:174–185
233. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ (2005) PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 292:43–52
234. Wang X, Meng D (2014) Innate endogenous adjuvants prime to desirable immune responses via mucosal routes, Protein Cell, 1–15
235. Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ (2009) Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J Virol 83:7166–7175
236. Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T et al (2012) Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 30:883–888
237. Wikingsson LD, Sjoholm I (2002) Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 20:3355–3363
238. Williamson ED, Oyston PC (2013) Protecting against plague: towards a next-generation vaccine. Clin Exp Immunol 172:1–8
239. Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279:3197–3201
240. Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q (2012) Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 8:823–827
241. Yoo MK, Kang SK, Choi JH, Park IK, Na HS, Lee HC, Kim EB, Lee NK, Nah JW, Choi YJ et al (2010) Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials 31:7738–7747
242. Yoshikawa T, Suzuki Y, Nomoto A, Sata T, Kurata T, Tamura S (2002) Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine 21:60–66
243. Zhang P, Yang QB, Marciani DJ, Martin M, Clements JD, Michalek SM, Katz J (2003) Effectiveness of the quillaja saponin semisynthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine 21:4459–4471
244. Zhang N, Jiang S, Du L (2014) Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 13:761–774
245. Zhao Q, Li S, Yu H, Xia N, Modis Y (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 31:654–663
246. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (2014) Nanoparticle vaccines. Vaccine 32:327–337
247. Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y et al (2012) Large intestinetargeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med 18:1291–1296